Wikipedia:WikiProject Chemicals/Chembox validation/VerifiedDataSandbox and Bemiparin sodium: Difference between pages

{{Short description|Chemical compound}}

| verifiedrevid = 461744899

| IUPAC_name =

| image = File:Heparin General Structure V.1.svg

<!-- Clinical data -->

| tradename = Badyket, Ivor, Hibor, Zibor, others

| pregnancy_category =

| legal_status =

| routes_of_administration = [[Subcutaneous injection]] (except for [[haemodialysis]])

<!-- Pharmacokinetic data -->

| bioavailability = 96% (estimated)

| protein_bound =

| metabolism =

| elimination_half-life = 5–6 hours

| excretion =

<!-- Identifiers -->

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 91449-79-5

| PubChem =

| DrugBank_Ref = {{drugbankcite|changed|drugbank}}

| DrugBank = DB09258

| ChemSpiderID = none

<!-- Chemical data -->

| chemical_formula =

| molecular_weight = 3600

| molecular_weight_comment = g/mol (average)

'''Bemiparin''' (trade names '''Ivor''' and '''Zibor''', among others) is an [[antithrombotic]] and belongs to the group of [[low molecular weight heparin]]s (LMWH).<ref>{{cite journal | vauthors = Chapman TM, Goa KL | title = Bemiparin: a review of its use in the prevention of venous thromboembolism and treatment of deep vein thrombosis | journal = Drugs | volume = 63 | issue = 21 | pages = 2357–77 | year = 2003 | pmid = 14524738 | doi = 10.2165/00003495-200363210-00009 | s2cid = 195692039 }}</ref>

==Medical uses==

Bemiparin is used for the prevention of [[thromboembolism]] after surgery, and to prevent blood clotting in the [[extracorporeal]] circuit in [[haemodialysis]].<ref name="AC">{{cite book|title=Austria-Codex|at=Ivor 2500 IE Anti-Xa/0,2 ml Injektionslösung in Fertigspritzen|publisher=Österreichischer Apothekerverlag|location=Vienna|year=2018|language=de}}</ref>

==Contraindications==

The medication is contraindicated in patients with a history of [[heparin-induced thrombocytopenia]] with or without [[disseminated intravascular coagulation]]; acute bleeding or risk of bleeding; injury or surgery of the central nervous system, eyes or ears; severe liver or [[pancreas]] impairment; and acute or [[subacute bacterial endocarditis]].<ref name="AC" />

== Interactions ==

No interaction studies have been conducted. Drugs that are expected to increase the risk of bleeding in combination with bemiparin include other anticoagulants, [[aspirin]] and other [[NSAID]]s, [[antiplatelet drug]]s, and [[corticosteroid]]s.<ref name="AC" />

==Chemistry==

Like [[semuloparin]], bemiparin is classified as an ultra-LMWH because of its low [[molecular mass]] of 3600 g/mol on average.<ref>{{cite journal | vauthors = Planès A | title = Review of bemiparin sodium--a new second-generation low molecular weight heparin and its applications in venous thromboembolism | journal = Expert Opinion on Pharmacotherapy | volume = 4 | issue = 9 | pages = 1551–61 | date = September 2003 | pmid = 12943485 | doi = 10.1517/14656566.4.9.1551 | s2cid = 13566575 }}</ref> ([[Enoxaparin]] has 4500 g/mol.) These heparins have lower anti-[[thrombin]] activity than classical LMWHs and act mainly on [[factor Xa]], reducing the risk of bleeding.<ref>{{cite journal | vauthors = Jeske WP, Hoppensteadt D, Gray A, Walenga JM, Cunanan J, Myers L, Fareed J, Bayol A, Rigal H, Viskov C | title = A common standard is inappropriate for determining the potency of ultra low molecular weight heparins such as semuloparin and bemiparin | journal = Thrombosis Research | volume = 128 | issue = 4 | pages = 361–7 | date = October 2011 | pmid = 21458847 | doi = 10.1016/j.thromres.2011.03.001 }}</ref>

== References ==

{{reflist}}

== External links ==

* {{MeshName|bemiparin}}

{{Antithrombotics}}

[[Category:Heparins]]

[[Category:Organic sodium salts]]